Back to Search
Start Over
Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
- Source :
- RMD Open
- Publication Year :
- 2019
- Publisher :
- BMJ Publishing Group, 2019.
-
Abstract
- ObjectivesTo evaluate the proportion of patients who have successfully withdrawn glucocorticoids (GCs) in a longitudinal cohort of patients with systemic lupus erythematosus (SLE) over a period of 6 years; to evaluate patient characteristics during GC withdrawal in relation to existing definitions of remission and Lupus Low Disease Activity State (LLDAS); and to evaluate the occurrence of flares after GC withdrawal.MethodsPatients who attempted GC withdrawal were identified for the cohort, and the following information was assessed during withdrawal attempts: date of last disease flare, disease activity and damage and ongoing treatment. Information regarding the occurrence of disease flares after GC withdrawal was also recorded for patients who successfully stopped treatment.Definitions of remission were applied to GC withdrawal in line with European consensus criteria (Definitions of remission in SLE [DORIS]) and LLDAS in line with the Asian Pacific Lupus Consortium definition.Results148 patients were involved in the study; GC withdrawal was attempted in 91 patients (61.5%) with 77 patients (84.6%) successfully stopping GCs. At the beginning of the GC reduction, the majority of patients were in complete or clinical remission (48.9% and 39.6%, respectively). Disease activity was significantly lower in patients who successfully stopped GCs, and the proportion of patients in complete remission was higher (54.2%) with respect to patients who failed in their attempt. Among patients who stopped GCs, 18 flares were recorded after a median of 1 year. The time period since the last flare was shorter in patients who experienced flares with respect to patients who did not flare (mean 0.93 years vs 6.0, pConclusionsGC withdrawal is an achievable goal in SLE and may be attempted after a long-term remission or LLDAS to protect the patient from disease flares.
- Subjects :
- Adult
medicine.medical_specialty
Immunology
Patient characteristics
Lupus
low disease activity state
Disease
Severity of Illness Index
Disease activity
03 medical and health sciences
0302 clinical medicine
remission
Rheumatology
Internal medicine
medicine
Immunology and Allergy
Humans
Lupus Erythematosus, Systemic
In patient
030212 general & internal medicine
Longitudinal Studies
Longitudinal cohort
skin and connective tissue diseases
glucocorticoids
Retrospective Studies
030203 arthritis & rheumatology
Systemic lupus erythematosus
business.industry
Remission Induction
Disease Management
Middle Aged
medicine.disease
Withholding Treatment
Cohort
Disease Progression
business
Glucocorticoid
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20565933
- Volume :
- 5
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- RMD Open
- Accession number :
- edsair.doi.dedup.....eb531c0b3686d9d00a495a8eaadb66ff